34 completed, 3 recruiting, 3 unknown, 2 withdrawn. 43 Phase 2, 4 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 43 | Completed 34, Recruiting 3, Unknown 3, Withdrawn 2, Suspended 1 |
| Phase 1 | 4 | Completed 2, Recruiting 1, Unknown 1 |
| Phase 3 | 4 | Completed 3, Suspended 1 |
Follow Levodopa: new trials by email Literature Review of Levodopa trials Research Report on Levodopa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Etoricoxib in Patients With Parkinsonian Disease L-dopa, Etoricoxib - Parkinson Disease | Phase 2 | Recruiting | Ihab Elsayed Hassan | 60 | 2026-01-30 | 2026-04-08 |
| Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. Administration of Carbidopa/levodopa - Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic | Phase 1 / Phase 2 | Recruiting | Julien Bally | 36 | 2025-07-18 | 2026-01-29 |
| Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations HRG2010(I), HRG2010(II), Sustained-release Carbidopa/Levodopa - Parkinson's Disease | Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 61 | 2023-05-16 | 2024-09-26 |
| Levodopa for Diabetic Retinopathy Levodopa, Placebo - Diabetic Retinopathy | Phase 2 | Completed | Emory University | 230 | 2022-04-18 | 2026-03-03 |
| Improving Therapeutic Learning for PTSD L-DOPA, Placebo - PTSD, Post Traumatic Stress Disorder | Phase 2 | Recruiting | University of Wisconsin, Madison | 120 | 2021-02-18 | 2023-08-30 |
| Dopaminergic Dysfunction in Late-Life Depression L-Dopa, Placebo - Late Life Depression, Cognitive Decline | Phase 2 | Completed | Vanderbilt University Medical Center | 79 | 2021-02-15 | 2026-08-06 |
| Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity carbidopa/levodopa and celecoxib, placebo1 and celecoxib, placebo1 and placebo2 - Chronic Back Pain | Phase 2 | Withdrawn | Second Affiliated Hospital of Wenzhou Medical University | 2019-10-01 | 2020-01-09 | |
| Effects of 5HTP and LDOPA on CNS Excitability After SCI 5HTP, L-DOPA, Placebo oral tablet - Spinal Cord Injuries | Phase 2 / Phase 3 | Suspended | Jessica M D'Amico | 30 | 2019-06-19 | 2022-10-17 |
| Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients Accordion Pill Carbidopa/Levodopa, Sinemet CR 25Mg-100Mg Extended-Release Tablet - Parkinson Disease | Phase 2 | Unknown | Intec Pharma Ltd. | 12 | 2018-07-01 | 2018-07-05 |
| Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal Placebo, L-dopa 35 mg, L-dopa 70mg - Parkinson's Disease | Phase 2 | Completed | Impel Pharmaceuticals | 32 | 2018-05-08 | 2020-08-12 |
| Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease NPC transplantation, Levodopa - Parkinson's Disease | Phase 1 / Phase 2 | Unknown | Chinese Academy of Sciences | 50 | 2017-05-01 | 2017-04-18 |
| A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease SAGE-217, Levodopa, Antiparkinsonian Agent(s) - Parkinson Disease | Phase 2 | Completed | Biogen | 29 | 2016-11-30 | 2023-11-29 |
| Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease PR Oxycodone, Levodopa, Oxycodone Placebo - Parkinson Disease | Phase 2 / Phase 3 | Completed | University Hospital, Toulouse | 67 | 2016-09-01 | 2026-05-04 |
| Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC) Stalevo, levodopa MR - Parkinson's Disease | Phase 2 | Completed | Orion Corporation, Orion Pharma | 84 | 2016-04-08 | 2018-04-05 |
| Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease CVXL-0107, Placebo, Levodopa - Idiopathic Parkinson Disease | Phase 2 | Completed | CleveXel Pharma | 21 | 2016-02-01 | 2017-07-24 |
| Mucuna Pruriens Therapy in Parkinson's Disease MP-Equivalent, MP-Low, MP+DDCI - Parkinson's Disease | Phase 2 | Completed | ASST Gaetano Pini-CTO | 18 | 2016-02-01 | 2016-10-05 |
| A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease ND0612 (Levodopa/Carbidopa solution), ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD - Parkinson's Disease | Phase 2 | Completed | NeuroDerm Ltd. | 38 | 2015-12-29 | 2023-05-25 |
| L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease L-dopa, Dopamine Agonists (pramipexole, ropirinole) - Parkinson's Disease | Phase 2 | Unknown | University of Toronto | 40 | 2015-01-01 | 2015-01-27 |
| Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse levodopa/carbidopa 400/100 BID - Cocaine Dependence | Phase 2 | Completed | Virginia Commonwealth University | 131 | 2014-02-01 | 2018-04-12 |
| A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients ND0612, Placebo, Entacapone - Parkinson's Disease | Phase 2 | Completed | NeuroDerm Ltd. | 30 | 2014-01-06 | 2026-07-09 |
Showing 20 of 43. Sign in to see all of them.
Parkinson Disease (31) · Dyskinesias (7) · Cocaine-Related Disorders (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Movement Disorders (2) · Neurodegenerative Diseases (2) · Spinal Cord Injuries (2) · Albinism (1) · Angelman Syndrome (1) · Cognitive Dysfunction (1) · Depressive Disorder, Major (1) · Depressive Disorder, Treatment-Resistant (1) · Diabetic Retinopathy (1) · Disease (1)
National Institute of Neurological Disorders and Stroke (NINDS) (6) · Bial - Portela C S.A. (3) · Merck Sharp & Dohme LLC (2) · NeuroDerm Ltd. (2) · The University of Texas Health Science Center, Houston (2) · ASST Gaetano Pini-CTO (1) · Acorda Therapeutics (1) · Biogen (1) · Biotie Therapies Inc. (1) · Centre for Addiction and Mental Health (1) · Chinese Academy of Sciences (1) · CleveXel Pharma (1) · Emory University (1) · Ihab Elsayed Hassan (1) · Impel Pharmaceuticals (1)
United States (21) · Canada (4) · China (3) · Israel (3) · Romania (3) · Ukraine (3) · France (2) · Italy (2) · Argentina (1) · Australia (1) · Austria (1) · Bolivia (1) · Chile (1) · Egypt (1) · Finland (1)
Aila Holopainen, MSc (1) · Alfonso Fasano, MD, PhD (1) · Andrew Hendrick, MD (1) · Ann Neale, RN (1) · Anne Slavotinek, MD (1) · BinBin Wu, doctor (1) · Carlos A. Bacino, MD (1) · Cary Fu, MD (1) · Danna Jennings, MD (1) · Gail Summers, M.D. (1) · Gary Remington, MD PhD FRCPC (1) · Gianni Pezzoli, MD (1)
PMID 21315654, PMID 23589371, PMID 25008546, PMID 28679598, PMID 29352722, PMID 29910127, PMID 33164945, PMID 35148289, PMID 38850081, PMID 41981270
2008 (1), 2009 (1), 2018 (1), P50DA009262 (1), R01DA023608 (1), R01DA034131 (1), R33MH108753 (1)